Sports moved to four-year bans on the assumption that time erases the advantage. This video from Tony Huge’s channel argues the assumption is wrong at the level of the cell. A muscle fiber is run by multiple nuclei, and a period of androgen use adds nuclei that do not leave when the drug does. That is muscle memory in the physical sense, and it is only the first of four pathways the video describes, each of which leaves a lasting upgrade: androgens add nuclei, IGF-1 adds fibers, estrogen expands the satellite cell pool, and EPO upgrades the fiber’s infrastructure. Stack them and you have a factory that has been permanently rebuilt.
Video: The Hidden PED That Stays in Your Muscles for Life. Published October 1, 2025. Watch on YouTube.
What the video covers
This video has no chapter markers; timestamps marked ~ are estimated from the transcript.
- ~00:00 The factory: Myonuclei as managers, and why hiring more of them is permanent.
- ~01:00 Myonuclear domains: Each nucleus controls a territory; satellite cells donate new nuclei.
- ~01:50 The animal and human data: Brief testosterone exposure, lasting nuclei, faster regrowth.
- ~02:40 The ethics problem: Four years off the power tools, but you keep the workshop.
- ~03:25 Pathway one, androgens: Androgen receptor, IGF-1 signaling, mTOR and satellite cell activation.
- ~04:20 Pathway two, IGF-1: Hyperplasia rather than hypertrophy: new fibers, not just bigger ones.
- ~05:30 Pathway three, estrogen: Satellite cell maintenance and expansion.
- ~06:20 Pathway four, EPO: Fiber diameter, glycogen, mitochondrial capacity, MYF6 and MyoD.
- ~07:10 Stacking: Why the pathways converge and compound.
- ~07:50 The long-term reality: Why a time-based ban cannot reset the baseline.
Managers who never leave
The video’s model is a factory. Each muscle fiber is run by many nuclei, the managers, and each nucleus governs its own territory, the myonuclear domain. More nuclei means a fiber can be managed at a larger size and rebuilt faster. When you train, or when you use performance enhancers, the body recruits satellite cells, which fuse with the fiber and donate their nuclei. New managers move in.
The claim that follows is the whole argument. The video cites animal studies in which a brief period of testosterone exposure produced a surge of new nuclei that persisted long after the hormone was gone, and when those animals later trained, they rebuilt muscle significantly faster than animals that had never been exposed. It then cites human work showing that former steroid users carry persistently higher myonuclei counts and better DNA-to-muscle ratios years after stopping. That is the biological advantage the title refers to: not the drug, which clears, but the cellular infrastructure it left behind.
“It’s like banning someone from using power tools for four years, but they get to keep the workshop that they built with those tools.”
Tony Huge’s channel, ~02:50
Why four years may not be enough
Sports bodies extended bans to four years to level the field. The video’s objection is that a time-based ban addresses the substance, not the upgrade. If the nuclei stay, four years is a timeout, and the athlete returns with a head start intact. The power tools analogy is the cleanest statement of it: you can confiscate the tools, but the workshop they built is still standing.
Four pathways, four kinds of permanence
The androgen receptor pathway is the first and the best documented. Testosterone and other anabolic steroids bind the androgen receptor, which activates IGF-1 signaling and the mTOR pathway, driving both satellite cell activation and protein synthesis. The permanent part is the added nuclei.
The IGF-1 pathway works differently, and the video treats it as the more dramatic one. High-dose growth hormone drives the liver to produce large amounts of IGF-1, and IGF-1 LR3 is a longer-lasting analog. Where androgens mostly enlarge existing fibers, IGF-1 is described as producing hyperplasia: new fibers, not just bigger ones. The video cites studies in which IGF-1 drives muscle development through hyperplasia and mitogenesis, and animal research in which muscle-specific growth hormone receptor overexpression induced hyperplasia. In the factory analogy, that is a new wing, and a new wing does not get demolished when the drug clears.
The estrogen pathway is the one most people would not expect. The video cites research showing that estrogen deficiency compromises satellite cell maintenance, that adequate estrogen keeps those cells healthy and ready, and that estrogen supplementation increases satellite cell numbers after exercise-induced damage. The permanent advantage here is a larger repair and growth crew standing by.
The EPO pathway is usually discussed as red blood cells, but the video points to direct effects on muscle: increased fiber diameter, glycogen content and mitochondrial capacity, enhanced regeneration after injury, and higher expression of growth factors such as MYF6 and MyoD. The lasting part is oxidative capacity and cellular infrastructure that persists after EPO levels normalize.
Stacking, and why it converges
The unfairness argument sharpens when the pathways combine. An athlete could use testosterone for nuclei, growth hormone and IGF-1 for new fibers, estrogen for a larger satellite cell pool, and EPO for upgraded infrastructure. Each leaves its own upgrade, and the video argues the effects are additive beyond any single pathway because they converge: IGF-1 activates satellite cells and mTOR, androgens act through their receptor and through IGF-1 activation, and both feed the same growth machinery. Multiple factory upgrades, none of which expire.
The long-term reality
The closing claim is that these changes appear permanent or extremely long-lasting: nuclei that persist for years, fiber numbers that stay elevated after hyperplasia, satellite cell populations that remain expanded, EPO-induced upgrades that outlast treatment. An athlete returning from a four-year ban is therefore not starting from the same baseline as a clean competitor. The video’s language is strong, that time-based bans “make a mockery” of the idea that serving your time levels the field, and its conclusion is that muscle memory is not neural or experiential. It is cellular, and it does not fade.
Cheat Sheet Pivot
What the video reports from the cited research, not instructions.
- Androgens add myonuclei via satellite cell fusion; animal studies show the added nuclei persist after brief exposure and enable faster regrowth, and human studies show elevated counts years after stopping.
- IGF-1, from high-dose growth hormone or IGF-1 LR3, is described as producing hyperplasia, new fibers rather than only larger ones.
- Estrogen maintains and expands the satellite cell pool; deficiency compromises it, supplementation increases it after damage.
- EPO increases fiber diameter, glycogen and mitochondrial capacity and raises MYF6 and MyoD expression, with oxidative upgrades persisting after treatment.
- The pathways converge on the same growth signaling, so stacking compounds the lasting effect.
Each of these compound classes is in the Miracle Molecules Cheat Sheet. For the research summaries behind the myonuclei claim, read Steroids’ Long-Term Muscle Memory Effects: Research Insights and Muscle Memory Discovery: What It Means for Bodybuilders.
Where the evidence stops
The video cites studies by finding rather than by name, so none can be checked from the transcript alone. The myonuclei persistence work is well known in animals and has human observational support, but “years” in humans comes from cross-sectional comparisons of former users, not from following the same people. The hyperplasia claim for IGF-1 in adult humans is far less settled than the video’s phrasing suggests; the strongest data are animal and overexpression models. The estrogen and EPO muscle effects are drawn from studies in specific populations and conditions and are generalized here. The ethical conclusion, that four-year bans cannot level the field, follows if the biology holds; the video does not weigh how large the residual advantage actually is in competitive terms. None of this is personal experience: it is a scripted explainer, and it should be read as a map of mechanisms rather than a set of measured outcomes.
Keep going
For the practical side of the same question, what you keep when the gear stops and why, read What Really Happens When You Stop the Gear, and for the compound class that breaks the usual rules, see 19-Nor Steroids Explained: Nandrolone, Trenbolone, and Why They Break the Rules. Companion articles reach the tonyhuge.is email list first, and the archive is on tonyhuge.is.